North America Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023

List of Tables

The North America Guillain-Barre Syndrome Market would witness market growth of 4.1% CAGR during the forecast period (2023-2030).

The US market dominated the North America Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $211,863.5 Thousands by 2030. The Canada market is experiencing a CAGR of 6.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.5% during (2023 - 2030).

The aging population has a significant impact on GBS. It primarily affects adults, with the highest incidence rates observed in individuals aged 50 and older. As the global population continues to age, there is a natural increase in the number of people at risk for GBS, contributing to the overall burden of the disease.

Additionally, by the Pan American Health Organization, more than 30 million individuals in Brazil were 60 years of age or elderly, accounting for 13 percent of the country's total population. By 2030, this age group will comprise 24 percent of the Brazilian population or approximately 50 million individuals.

As per the Government of Canada, in 2023, the government announced an investment of $196.1 billion over ten years, including $46.2 billion in new funding, for provinces and territories to improve health care services for Canadians. In addition, it will invest $2.5 billion over ten years to support indigenous priorities and complementary federal support, for a total of $198.6 billion over ten years.

Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
PTC, Inc.
AstraZeneca PLC
Novartis AG
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Bayer AG
Merck & Co., Inc.
Bristol Myers Squibb Company

North America Guillain-Barre Syndrome Market Report Segmentation

By Therapeutics

Intravenous Immunoglobulin
Plasma Exchange
Others

By Route Of Administration

Parenteral
Oral

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

By Country

US
Canada
Mexico
Rest of North America

Chapter 1.Market Scope & Methodology

1.1Market Definition
1.2Objectives
1.3Market Scope
1.4Segmentation
- 1.4.1North America Guillain-Barre Syndrome Market, by Therapeutics
- 1.4.2North America Guillain-Barre Syndrome Market, by Route Of Administration
- 1.4.3North America Guillain-Barre Syndrome Market, by Distribution Channel
- 1.4.4North America Guillain-Barre Syndrome Market, by Country
1.5Methodology for the research

Chapter 2.Market at a Glance

2.1Key Highlights

Chapter 3.Market Overview

3.1Introduction
- 3.1.1Overview
  - 3.1.1.1Market Composition and Scenario
3.2Key Factors Impacting the Market
- 3.2.1Market Drivers
- 3.2.2Market Restraints
- 3.2.3Market Opportunities
- 3.2.4Market Challenges
3.3Porter Five Forces Analysis

Chapter 4.North America Guillain-Barre Syndrome Market by Therapeutics

4.1North America Intravenous Immunoglobulin Market by Country
4.2North America Plasma Exchange Market by Country
4.3North America Others Market by Country

Chapter 5.North America Guillain-Barre Syndrome Market by Route Of Administration

5.1North America Parenteral Market by Country
5.2North America Oral Market by Country

Chapter 6.North America Guillain-Barre Syndrome Market by Distribution Channel

6.1North America Hospital Pharmacies Market by Country
6.2North America Retail Pharmacies Market by Country
6.3North America Others Market by Country

Chapter 7.North America Guillain-Barre Syndrome Market by Country

7.1US Guillain-Barre Syndrome Market
- 7.1.1US Guillain-Barre Syndrome Market by Therapeutics
- 7.1.2US Guillain-Barre Syndrome Market by Route Of Administration
- 7.1.3US Guillain-Barre Syndrome Market by Distribution Channel
7.2Canada Guillain-Barre Syndrome Market
- 7.2.1Canada Guillain-Barre Syndrome Market by Therapeutics
- 7.2.2Canada Guillain-Barre Syndrome Market by Route Of Administration
- 7.2.3Canada Guillain-Barre Syndrome Market by Distribution Channel
7.3Mexico Guillain-Barre Syndrome Market
- 7.3.1Mexico Guillain-Barre Syndrome Market by Therapeutics
- 7.3.2Mexico Guillain-Barre Syndrome Market by Route Of Administration
- 7.3.3Mexico Guillain-Barre Syndrome Market by Distribution Channel
7.4Rest of North America Guillain-Barre Syndrome Market
- 7.4.1Rest of North America Guillain-Barre Syndrome Market by Therapeutics
- 7.4.2Rest of North America Guillain-Barre Syndrome Market by Route Of Administration
- 7.4.3Rest of North America Guillain-Barre Syndrome Market by Distribution Channel

Chapter 8.Company Profiles

8.1F. Hoffmann-La Roche Ltd.
- 8.1.1Company Overview
- 8.1.2Financial Analysis
- 8.1.3Segmental and Regional Analysis
- 8.1.4Research & Development Expense
- 8.1.5SWOT Analysis
8.2Pfizer, Inc.
- 8.2.1Company Overview
- 8.2.2Financial Analysis
- 8.2.3Regional & Segmental Analysis
- 8.2.4Research & Development Expense
- 8.2.5SWOT Analysis
8.3PTC, Inc.
- 8.3.1Company Overview
- 8.3.2Financial Analysis
- 8.3.3Segmental and Regional Analysis
- 8.3.4Research & Development Expenses
- 8.3.5SWOT Analysis
8.4AstraZeneca PLC
- 8.4.1Company Overview
- 8.4.2Financial Analysis
- 8.4.3Regional Analysis
- 8.4.4Research & Development Expenses
- 8.4.5SWOT Analysis
8.5Novartis AG
- 8.5.1Company Overview
- 8.5.2Financial Analysis
- 8.5.3Segmental and Regional Analysis
- 8.5.4Research & Development Expense
- 8.5.5Recent strategies and developments:
  - 8.5.5.1Partnerships, Collaborations, and Agreements:
- 8.5.6SWOT Analysis
8.6Novo Nordisk A/S
- 8.6.1Company Overview
- 8.6.2Financial Analysis
- 8.6.3Segmental and Regional Analysis
- 8.6.4Research & Development Expenses
- 8.6.5SWOT Analysis
8.7Takeda Pharmaceutical Company Limited
- 8.7.1Company Overview
- 8.7.2Financial Analysis
- 8.7.3Regional Analysis
- 8.7.4Research & Development Expense
- 8.7.5SWOT Analysis
8.8Bayer AG
- 8.8.1Company Overview
- 8.8.2Financial Analysis
- 8.8.3Segmental and Regional Analysis
- 8.8.4Research & Development Expense
- 8.8.5SWOT Analysis
8.9Merck & Co., Inc.
- 8.9.1Company Overview
- 8.9.2Financial Analysis
- 8.9.3Segmental and Regional Analysis
- 8.9.4Research & Development Expenses
- 8.9.5Recent strategies and developments:
  - 8.9.5.1Partnerships, Collaborations, and Agreements:
- 8.9.6SWOT Analysis
8.10.Bristol Myers Squibb Company
- 8.10.1Company Overview
- 8.10.2Financial Analysis
- 8.10.3Regional Analysis
- 8.10.4Research & Development Expenses
- 8.10.5SWOT Analysis

LIST OF TABLES

TABLE 1North America Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 2North America Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 3North America Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 4North America Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 5North America Intravenous Immunoglobulin Market by Country, 2019 - 2022, USD Thousands
TABLE 6North America Intravenous Immunoglobulin Market by Country, 2023 - 2030, USD Thousands
TABLE 7North America Plasma Exchange Market by Country, 2019 - 2022, USD Thousands
TABLE 8North America Plasma Exchange Market by Country, 2023 - 2030, USD Thousands
TABLE 9North America Others Market by Country, 2019 - 2022, USD Thousands
TABLE 10North America Others Market by Country, 2023 - 2030, USD Thousands
TABLE 11North America Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 12North America Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 13North America Parenteral Market by Country, 2019 - 2022, USD Thousands
TABLE 14North America Parenteral Market by Country, 2023 - 2030, USD Thousands
TABLE 15North America Oral Market by Country, 2019 - 2022, USD Thousands
TABLE 16North America Oral Market by Country, 2023 - 2030, USD Thousands
TABLE 17North America Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 18North America Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 19North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Thousands
TABLE 20North America Hospital Pharmacies Market by Country, 2023 - 2030, USD Thousands
TABLE 21North America Retail Pharmacies Market by Country, 2019 - 2022, USD Thousands
TABLE 22North America Retail Pharmacies Market by Country, 2023 - 2030, USD Thousands
TABLE 23North America Others Market by Country, 2019 - 2022, USD Thousands
TABLE 24North America Others Market by Country, 2023 - 2030, USD Thousands
TABLE 25North America Guillain-Barre Syndrome Market by Country, 2019 - 2022, USD Thousands
TABLE 26North America Guillain-Barre Syndrome Market by Country, 2023 - 2030, USD Thousands
TABLE 27US Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 28US Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 29US Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 30US Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 31US Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 32US Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 33US Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 34US Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 35Canada Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 36Canada Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 37Canada Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 38Canada Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 39Canada Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 40Canada Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 41Canada Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 42Canada Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 43Mexico Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 44Mexico Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 45Mexico Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 46Mexico Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 47Mexico Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 48Mexico Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 49Mexico Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 50Mexico Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 51Rest of North America Guillain-Barre Syndrome Market, 2019 - 2022, USD Thousands
TABLE 52Rest of North America Guillain-Barre Syndrome Market, 2023 - 2030, USD Thousands
TABLE 53Rest of North America Guillain-Barre Syndrome Market by Therapeutics, 2019 - 2022, USD Thousands
TABLE 54Rest of North America Guillain-Barre Syndrome Market by Therapeutics, 2023 - 2030, USD Thousands
TABLE 55Rest of North America Guillain-Barre Syndrome Market by Route Of Administration, 2019 - 2022, USD Thousands
TABLE 56Rest of North America Guillain-Barre Syndrome Market by Route Of Administration, 2023 - 2030, USD Thousands
TABLE 57Rest of North America Guillain-Barre Syndrome Market by Distribution Channel, 2019 - 2022, USD Thousands
TABLE 58Rest of North America Guillain-Barre Syndrome Market by Distribution Channel, 2023 - 2030, USD Thousands
TABLE 59Key Information - F. Hoffmann-La Roche Ltd.
TABLE 60Key Information - Pfizer, Inc.
TABLE 61key Information - PTC, Inc.
TABLE 62KEY INFORMATION - AstraZeneca PLC
TABLE 63Key Information - Novartis AG
TABLE 64Key Information - Novo Nordisk A/S
TABLE 65Key Information - Takeda Pharmaceutical Company Limited
TABLE 66Key Information - Bayer AG
TABLE 67Key Information - Merck & Co., Inc.
TABLE 68Key Information - Bristol Myers Squibb Company

North America Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report By Therapeutics (Intravenous Immunoglobulin, Plasma Exchange, and Others), By Route Of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

Description

Table of Contents